NCT05575986

Herombopag Olamine in the Treatment of Thrombocytopenia After Chemotherapy

An Exploring Single Arm Study on the Efficacy and Safety of Herombopag Olamine in the Treatment of Thrombocytopenia After Chemotherapy in Malignant Tumors of the Digestive System

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: Huazhong University of Science and Technology · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the efficacy and safety of hetrombopag in the treatment of thrombocytopenia after chemotherapy in patients with digestive system malignant tumors

Conditions

• Malignant Tumors of the Digestive System
• Trombocitopenia

Interventions

Type	Name	Description
DRUG	Hetrombopag Olamine	Hetrombopag Olamine 7.5mg orally, once a day, for 14 days. This product should be taken on an empty stomach, 2 hours after oral administration before eating, avoid taking it with meals.

Timeline

• Start date: 2022-10-01
• Primary completion: 2023-10-01
• Completion: 2023-12-01
• First posted: 2022-10-12
• Last updated: 2022-10-12

Locations

1 site across 1 country: China